SynthesisNeurosurgical review2025
The efficacy and safety of Bevacizumab-based treatments in Optic Pathway Glioma among pediatric population: a systematic review and meta-analysis.
Synthesis in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Precision diagnosis and therapy for pediatric central nervous system tumors: consensus from the Brazilian Society of Pediatric Oncology (SOBOPE).Lancet regional health. Americas · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The optimal therapeutic intervention for pediatrics with optic pathway glioma (OPG) remained controversial in the literature. Recently, due to substantial adverse events (AEs) of chemotherapy and its impact on children's lives, the efficacy of other options has been investigated. Bevacizumab (BVZ) is an anti-vascular endothelial growth factor (VEGF) agent that alters the lesion microenvironment. In this systematic review and meta-analysis, we aimed to evaluate the efficacy of BVZ-based treatment (BBT) in pediatrics with OPG. The electronic databases of PubMed/Medline, Scopus, Embase, and Web of Science were searched from inception to 15 October 2024. The R program performed the meta-analyses, sensitivity analysis, publication bias, and meta-regression. A total of ten studies with 185 patients were included. Our meta-analysis revealed a pooled local control rate of 80% (95% CI: 60-91%), radiological response rate of 18% (95% CI: 6-41%), stable disease rate of 57% (95% CI: 39-73%), and progression rate of 20% (95% CI: 9-40%). Our results demonstrated a pooled visual acuity (VA) improvement rate of 31% (95% CI: 24-39%), a stable rate of 60% (95% CI: 52- 67%), and a worsening rate of 15% (95% CI: 6 - 30%). Our meta-analysis revealed a pooled VF improvement rate of 40% (95% CI: 20- 64%) and a worsening rate of 18% (95% CI: 10 - 30%). BBT is associated with favorable outcomes and a low occurrence rate of severe AE and could be considered a promising therapeutic option in children with OPG.
Indexed as
Identifiers
39849189What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.